Goldman Sachs Sees 46% Upside in NIO as It Upgrades Rating to Buy
Strong deliveries, premium margins, and expected 2026 profitability drive the bullish call.
Already have an account? Sign in.
Strong deliveries, premium margins, and expected 2026 profitability drive the bullish call.
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.
June sales set a new monthly record. Full earnings expected July 16.
The Florida-based surgical device maker faces margin pressures but sees strong interest from acquirers.